[{"orgOrder":0,"company":"Ambio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambio Announces US FDA Approval of a Generic Version of Forteo\u00ae (Teriparatide Injection) for Its Partner Apotex","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV"},{"orgOrder":0,"company":"Ambio","sponsor":"Apotex Fermentation Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Ambio
Forteo-Generic (teriparatide) is a parathyroid hormone analog, (PTH 1-34), which is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.